Intercept Pharmaceuticals Prices at $15, Raises $75M in IPO
October 12, 2012
Intercept Pharmaceuticals raised $75 million in its IPO by offering 5 million shares priced at $15 apiece, at the upper end of its proposed range of $13 to $15. The biopharmaceutical company is developing therapeutics to treat chronic liver disease. In mid-August, OrbiMed Advisors led the company's last round before it went public—a $30 million Series C financing.